Princeton: Bristol Myers Squibb has received approval from the European Commission (EC) for a new Opdivo (nivolumab) formulation associated with a new route of administration (subcutaneous use [SC]), ...

CheckMate -67T was a phase 3, randomized, open-label, noninferiority trial evaluating Opdivo Qvantig compared to intravenous (IV) Opdivo, in adult patients with advanced or metastatic clear cell renal ...

OPDIVO ® is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.

The safety profile of subcutaneous Opdivo was consistent with the IV formulation. The pharmacokinetics, efficacy and safety results from CheckMate -67T were presented at the 2024 American Society of ...

PRINCETON, N.J., February 19, 2025--BMS Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant ...

Find out about possible interactions between Opdivo and other medications, supplements, alcohol, foods, and more.

In the interview, he delved into detail on the significance of this FDA approval for patients with solid tumors who may be treated with Opdivo, as well as explained the benefits that are offered with ...

Opdivo Qvantig was co-formulated with Halozyme Therapeutics' drug delivery technology, which helps reduce treatment administration from hours-long IV infusions to subcutaneous injections delivered ...

The FDA approval is based on positive results from the Phase 3 CheckMate-67T study, evaluating Opdivo Qvantig co-formulated with Halozyme's ENHANZE, compared to intravenous Opdivo, in adults with ...